S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
NASDAQ:CABA

Cabaletta Bio (CABA) Stock Forecast, Price & News

$15.22
+0.02 (+0.13%)
(As of 09/29/2023 ET)
Compare
Today's Range
$15.05
$15.48
50-Day Range
$11.84
$18.65
52-Week Range
$0.63
$19.34
Volume
596,887 shs
Average Volume
1.05 million shs
Market Capitalization
$605.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Cabaletta Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
38.0% Upside
$21.00 Price Target
Short Interest
Bearish
7.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.29mentions of Cabaletta Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$492,910 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.51) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

528th out of 972 stocks

Biological Products, Except Diagnostic Industry

77th out of 155 stocks


CABA stock logo

About Cabaletta Bio (NASDAQ:CABA) Stock

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Price History

CABA Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Analyst Ratings for Cabaletta Bio
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Cabaletta Bio (CABA) Receives a Buy from Citi
H.C. Wainwright Sticks to Its Buy Rating for Cabaletta Bio (CABA)
Top Growth Stocks for August 2023
See More Headlines
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CABA
Fax
N/A
Employees
77
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$39.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+38.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-52,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.60 per share

Miscellaneous

Free Float
34,897,000
Market Cap
$605.91 million
Optionable
Not Optionable
Beta
2.55
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Steven A. Nichtberger M.D. (Age 62)
    Co-Founder, Chairman, CEO & Pres
    Comp: $970.6k
  • Dr. Gwendolyn K. Binder Ph.D. (Age 48)
    Pres of Science & Technology
    Comp: $692.99k
  • Dr. David J. Chang FACR (Age 60)
    M.D., M.P.H., Chief Medical Officer
    Comp: $676.74k
  • Dr. Michael C. Milone M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Dr. Aimee Payne M.D.
    Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Mr. Anup Marda M.B.A. (Age 46)
    Chief Financial Officer
  • Dr. Samik Basu M.D.
    Chief Scientific Officer
  • Mr. Michael Gerard J.D. (Age 43)
    Gen. Counsel & Sec.
  • Ms. Heather Harte-Hall M.Sc.
    Chief Compliance Officer
  • Ms. Martha O'Connor
    Chief HR Officer













CABA Stock - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CABA shares.
View CABA analyst ratings
or view top-rated stocks.

What is Cabaletta Bio's stock price forecast for 2023?

7 Wall Street research analysts have issued twelve-month target prices for Cabaletta Bio's stock. Their CABA share price forecasts range from $10.00 to $39.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 38.0% from the stock's current price.
View analysts price targets for CABA
or view top-rated stocks among Wall Street analysts.

How have CABA shares performed in 2023?

Cabaletta Bio's stock was trading at $9.25 on January 1st, 2023. Since then, CABA stock has increased by 64.5% and is now trading at $15.22.
View the best growth stocks for 2023 here
.

When is Cabaletta Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CABA earnings forecast
.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) released its earnings results on Thursday, August, 10th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.10.

What ETFs hold Cabaletta Bio's stock?

ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.

What is Cabaletta Bio's stock symbol?

Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."

How do I buy shares of Cabaletta Bio?

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cabaletta Bio's stock price today?

One share of CABA stock can currently be purchased for approximately $15.22.

How much money does Cabaletta Bio make?

Cabaletta Bio (NASDAQ:CABA) has a market capitalization of $605.91 million. The company earns $-52,970,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.

How can I contact Cabaletta Bio?

Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The official website for the company is www.cabalettabio.com. The company can be reached via phone at 267-759-3100 or via email at investors@cabalettabio.com.

This page (NASDAQ:CABA) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -